Salarius Pharmaceuticals Secures $7 Million Through Public Offering to Fund Oncology Research Salarius Pharmaceuticals recently announced a $7 million underwritten public offering aimed at financing its clinical oncology programs and merger with Decoy Therapeutics.

Salarius Pharmaceuticals Secures $7 Million Through Public Offering to Fund Oncology Research #USA #Houston #Clinical_Trials #Salarius_Pharmaceuticals #Decoy_Therapeutics